Texas Doctors Who Still Accept New Medicare Patients Down By 32 Percent. Doctors in Texas are shying away from taking in new Medicare patients because of reductions in reimbursements. Fri, 4 Jul 2008 11:48:10 GMT.

Low Levels Of Maternal Vitamin D Linked To Dental Problems In Babies. Pregnant women who consumed low levels of vitamin D during gestation are more likely to have babies who develop tooth enamel problems, which can lead to tooth decay, new Canadian research says. Fri, 4 Jul 2008 20:49:51 GMT.

Study: Women Receiving Kidneys From Males Donors At High Risk Of Organ Rejection. Women receiving kidneys from males donors are at a higher risk of organ rejection than those who received from same gender, a new Swiss study says. Sat, 5 Jul 2008 09:00:54 GMT.

A Star Falling, by Choice, to Earth. UNDISCOVERED By Debra Winger Simon & Schuster. 188 pp. $23.

The Campaign Season's Dog Days. The latest angle on the presidential race: Which pooch will roam the halls of the White House?.

Leading With Their Left. John McCain may veer to the right, but make no mistake: The Republican presidential contender is a born lefty, just like his Democratic counterpart, Barack Obama.

Greer Completes Enrollment For Pivotal Phase III Trial Evaluating The Efficacy Of Sublingual-Oral Immunotherapy For Treating Short Ragweed Allergies. Greer, a leading developer and provider of allergy immunotherapy products and services, has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen. It is estimated that 30 million Americans are allergic to short ragweed pollen, making it one of the most common allergens.

Echo Therapeutics Initiates Clinical Study Of Its Symphony Transdermal Continuous Glucose Monitoring System In Patients With Diabetes. Echo Therapeutics, Inc. announced that it has initiated a clinical study of its Symphony Transdermal Continuous Glucose Monitoring System in patients with Type 1 and Type 2 diabetes. The Company expects to complete and announce the results of the study in the third quarter of 2008.

ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial Of CoFactor. ADVENTRX Pharmaceuticals, Inc. announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5-FU, for the treatment of first-line metastatic colorectal cancer. The primary endpoint of the study was progression-free survival, which is expected to mature and be reported by the Company along with safety data later this year.

Peregrine Pharmaceuticals Reports Positive Early Results In Phase II Study Of Bavituximab In Breast Cancer. Peregrine Pharmaceuticals, Inc. reported that its lead product candidate bavituximab achieved the pre-specified Stage 1 primary endpoint in its ongoing Phase II clinical trial in patients with metastatic breast cancer. The trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of a combination of bavituximab and docetaxel in metastatic breast cancer patients.

Salix Initiates Phase 3 For Rifaximin In Non-Constipation Irritable Bowel Syndrome. Salix Pharmaceuticals, Ltd. announced that the Company has initiated patient enrollment in TARGET 1 and TARGET 2, its Phase 3, randomized, double-blind, placebo-controlled, multicenter studies to assess the efficacy and safety of rifaximin 550 mg, dosed three times daily, in the treatment of subjects with non-constipation irritable bowel syndrome.

Advanced Thyroid Cancer Investigational Drug Shows Promise. A study by an international team of researchers found that an experimental drug that stops blood vessels that feed tumors from forming was able, in a small number of patients, to slow down the progression of advanced thyroid cancer that has spread to other sites.

M0002 Progresses To Phase IIb Trial Following Positive Results In Cirrhotic Ascites. Movetis NV, a European specialist pharmaceutical company, announced that M0002 is progressing to phase IIb following positive results of a phase IIa multiple-dosing trial for the treatment of ascites, the accumulation of fluid in the abdomen in patients with liver cirrhosis resulting from liver conditions such as hepatitis C, hepatitis B or alcoholism.

Omrix Biopharmaceuticals Initiates Phase II Clinical Trial In Israel For Fibrin Pad Product Candidate. Omrix Biopharmaceuticals, Inc. announced that it has enrolled its first patient in a Phase II clinical trial in Israel for its Fibrin Pad product candidate. This is the first clinical trial that will evaluate the Fibrin Pad's performance in surgery where severe bleeding is present and the product is applied directly onto a solid organ. The Phase II clinical trial in Israel is being conducted simultaneously with the Phase II clinical trial in the U.S.

WVU faculty mull ways to help pick new president. Leaders of the West Virginia University Faculty Senate are meeting Monday to discuss how educators can best influence the selection of both an interim and a permanent president to help restore the school's..

Yer Biotech Blues: From infectious disease to cancer - 60 years of pharma growth. Reproduction permitted for personal use only. For reprints and reprint permission, contact Yer Biotech Blues From infectious disease to cancer - 60 years of pharma growth When I..

Barr announces favorable ruling in Mirapex patent challenge. Barr Pharmaceuticals, Inc. has announced that U.S. District Court for Delaware has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Boehringer Ingelheim..

Par Pharmaceutical Receives Final Approval to Market Generic Marinol CIII Capsules. Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for dronabinol, a generic version of..

Bentley Pharmaceuticals & Teva Pharmaceutical Industries Ltd. Merger.. Bentley Pharmaceuticals, Inc. announced that the aggregate cash purchase price for its acquisition by Teva Pharmaceutical Industries Ltd.

ATL/TV1102, A Novel Drug For The Treatment Of Relapsing Remitting.. Teva Pharmaceutical Industries Ltd. and Antisense Therapeutics Ltd. announced that ATL/TV1102, a novel, anti-sense drug, significantly reduced disease activity in patients with relapsing-remitting multiple..